418 related articles for article (PubMed ID: 9252074)
1. Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial.
Saracco G; Borghesio E; Mesina P; Solinas A; Spezia C; Macor F; Gallo V; Chiandussi L; Donada C; Donadon V; Spirito F; Mangia A; Andriulli A; Verme G; Rizzetto M
J Hepatol; 1997 Jul; 27(1):56-62. PubMed ID: 9252074
[TBL] [Abstract][Full Text] [Related]
2. Long-term lymphoblastoid interferon-alpha therapy for non-cirrhotic chronic hepatitis C: an Italian multicentre study on dose and duration of IFN alpha treatment.
Piccinino F; Felaco FM; Sagnelli E; Aprea L; Messina V; Pasquale G; Filippini P; Scolastico C
Res Virol; 1998; 149(5):283-91. PubMed ID: 9879606
[TBL] [Abstract][Full Text] [Related]
3. HCV-RNA levels play an important role independently of genotype in predicting response to interferon therapy.
Picciotto A; Campo N; Brizzolara R; Sinelli N; Poggi G; Grasso S; Celle G
Eur J Gastroenterol Hepatol; 1997 Jan; 9(1):67-9. PubMed ID: 9031902
[TBL] [Abstract][Full Text] [Related]
4. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
[TBL] [Abstract][Full Text] [Related]
5. Dose increase augments response rate to interferon-alpha in chronic hepatitis C.
Ferenci P; Stauber R; Propst A; Fiedler R; Müller C; Gschwantler M; Schütze K; Datz C; Judmaier G; Vogel W; Krejs GJ; Gangl A
Dig Dis Sci; 1996 Dec; 41(12 Suppl):103S-108S. PubMed ID: 9011466
[TBL] [Abstract][Full Text] [Related]
6. Treatment with interferon-alpha2b of naive non-cirrhotic patients with chronic hepatitis C according to viraemia and genotype. Results of a randomized multicentre study. The North West Italian Hepatological Group.
Saracco G; Ciancio A; Ghisetti V; Rocca G; Cariti G; Andreoni M; Tabone M; Roffi L; Calleri G; Ballaré M; Terreni N; Sartori M; Tappero GF; Traverso A; Poggio A; Orani A; Maggi G; Di Napoli A; Arrigoni A; Rizzetto M;
Eur J Gastroenterol Hepatol; 2001 Feb; 13(2):149-55. PubMed ID: 11246614
[TBL] [Abstract][Full Text] [Related]
7. A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, France.
Pol S; Couzigou P; Bourlière M; Abergel A; Combis JM; Larrey D; Tran A; Moussalli J; Poupon R; Berthelot P; Bréchot C
J Hepatol; 1999 Jul; 31(1):1-7. PubMed ID: 10424277
[TBL] [Abstract][Full Text] [Related]
8. Viral and host factors in determining response of relapsers with chronic hepatitis C to retreatment with interferon.
Almasio PL; Di Marco V; Bonura C; Fuschi P; Camma C; Lo Iacono O; Artini M; Natoli C; Di Stefano R; Levrero M; Craxi A
Dig Dis Sci; 1999 May; 44(5):1013-9. PubMed ID: 10235612
[TBL] [Abstract][Full Text] [Related]
9. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatitis Interventional Therapy Group.
Lindsay KL; Davis GL; Schiff ER; Bodenheimer HC; Balart LA; Dienstag JL; Perrillo RP; Tamburro CH; Goff JS; Everson GT; Silva M; Katkov WN; Goodman Z; Lau JY; Maertens G; Gogate J; Sanghvi B; Albrecht J
Hepatology; 1996 Nov; 24(5):1034-40. PubMed ID: 8903371
[TBL] [Abstract][Full Text] [Related]
10. Genotype, viral load and age as independent predictors of treatment outcome of interferon-alpha 2a treatment in patients with chronic hepatitis C. Construct group.
Bell H; Hellum K; Harthug S; Maeland A; Ritland S; Myrvang B; von der Lippe B; Raknerud N; Skaug K; Gutigard BG; Skjaerven R; Prescott LE; Simmonds P
Scand J Infect Dis; 1997; 29(1):17-22. PubMed ID: 9112292
[TBL] [Abstract][Full Text] [Related]
11. A multicenter, randomized, controlled trial of interferon alfacon-1 compared with alpha-2a-interferon in Chinese patients with chronic hepatitis C virus infection.
Yao GB; Fu XX; Tian GS; Xu DZ; Hao LJ; Huangfu YS; Su CX
J Gastroenterol Hepatol; 2000 Oct; 15(10):1165-70. PubMed ID: 11106097
[TBL] [Abstract][Full Text] [Related]
12. A randomized controlled trial of high-dose maintenance interferon therapy in chronic hepatitis C.
Di Marco V; Lo Iacono O; Cammà C; Almasio PL; Vaccaro A; Fuschi P; Giunta M; Fabiano C; Pagliaro L; Craxì A
J Med Virol; 1997 Jan; 51(1):17-24. PubMed ID: 8986944
[TBL] [Abstract][Full Text] [Related]
13. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
Farrell GC; Bacon BR; Goldin RD
Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
[TBL] [Abstract][Full Text] [Related]
14. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C. TriVeneto Viral Hepatitis Group.
Chemello L; Cavalletto L; Casarin C; Bonetti P; Bernardinello E; Pontisso P; Donada C; Belussi F; Martinelli S; Alberti A
Ann Intern Med; 1996 Jun; 124(12):1058-60. PubMed ID: 8633819
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients.
Brouwer JT; Nevens F; Kleter B; Elewaut A; Adler M; Brenard R; Chamuleau RA; Michielsen PP; Pirotte J; Hautekeete ML; Weber J; Bourgeois N; Hansen BE; Bronkhorst CM; ten Kate FJ; Heijtink RA; Fevery J; Schalm SW
J Hepatol; 1998 Jun; 28(6):951-9. PubMed ID: 9672169
[TBL] [Abstract][Full Text] [Related]
16. The clinical value of grading and staging scores for predicting a long-term response and evaluating the efficacy of interferon therapy in chronic hepatitis C.
Shindo M; Arai K; Okuno T
J Hepatol; 1997 Mar; 26(3):492-7. PubMed ID: 9075654
[TBL] [Abstract][Full Text] [Related]
17. Effect of interferon-alpha induction therapy on genotype 2b/3a and low viral load hepatitis C virus infection. A randomized multicentre study.
Bjøro K; Bell H; Myrvang B; Skaug K; Raknerud N; Sandvei P; Størseth S; Ritland S; Lund-Tønnesen S; Bucher A; Hellum KB
Scand J Gastroenterol; 2002 Mar; 37(3):344-9. PubMed ID: 11916198
[TBL] [Abstract][Full Text] [Related]
18. Low dose alpha interferon therapy can be effective in chronic active hepatitis C. Results of a multicentre, randomised trial.
Sánchez-Tapias JM; Forns X; Ampurdanés S; Titó L; Planas R; Viver JM; Acero D; Torres M; Mas P; Morillas R; Forné M; Espinós J; Llovet JM; Costa J; Olmedo E; López-Labrador FX; Jiménez de Anta MT; Rodés J
Gut; 1996 Apr; 38(4):603-9. PubMed ID: 8707096
[TBL] [Abstract][Full Text] [Related]
19. Treatment of chronic hepatitis C with interferon-alpha. Clinical histological and virological implications.
Olaso V; Córdoba J; Berenguer M; Prieto M; Lainez B; Argüello L; Valverde J; Pascual S; Gobernado M; Berenguer J
Rev Esp Enferm Dig; 1997 Jul; 89(7):531-50. PubMed ID: 9265839
[TBL] [Abstract][Full Text] [Related]
20. Patterns of hepatitis C viremia in patients receiving hemodialysis.
Umlauft F; Gruenewald K; Weiss G; Kessler H; Urbanek M; Haun M; Santner B; Koenig P; Keeffe EB
Am J Gastroenterol; 1997 Jan; 92(1):73-8. PubMed ID: 8995941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
